Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2013 2
2014 1
2015 1
2016 1
2019 3
2020 2
2021 3
2022 3
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Access to Oncology Medicines in Canada: Consensus Forum for Recommendations for Improvement.
Sehdev SR, Rawson NSB, Aseyev OI, Buick CJ, Butler MO, Edwards S, Gill S, Gotfrit JM, Hsia CC, Juergens RA, Manna M, McCarthy JS, Mukherjee SD, Snow SL, Spadafora S, Stewart DJ, Wentzell JR, Wong RPW, Zalewski PG. Sehdev SR, et al. Curr Oncol. 2024 Mar 29;31(4):1803-1816. doi: 10.3390/curroncol31040136. Curr Oncol. 2024. PMID: 38668039 Free PMC article.
Correction to: Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel.
Papp KA, Melosky B, Sehdev S, Hotte SJ, Beecker JR, Kirchhof MG, Turchin I, Dutz JP, Gooderham MJ, Gniadecki R, Hong CH, Lambert J, Lynde CW, Prajapati VH, Vender RB. Papp KA, et al. Among authors: sehdev s. Dermatol Ther (Heidelb). 2023 Aug;13(8):1889-1890. doi: 10.1007/s13555-023-00949-5. Dermatol Ther (Heidelb). 2023. PMID: 37410207 Free PMC article. No abstract available.
Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm.
Yang C, Brezden-Masley C, Joy AA, Sehdev S, Modi S, Simmons C, Henning JW. Yang C, et al. Among authors: sehdev s. Ther Adv Med Oncol. 2023 Jun 5;15:17588359231175440. doi: 10.1177/17588359231175440. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37323186 Free PMC article. Review.
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, Su WC, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenkov Y, Wu YL; ADAURA Investigators. Tsuboi M, et al. N Engl J Med. 2023 Jul 13;389(2):137-147. doi: 10.1056/NEJMoa2304594. Epub 2023 Jun 4. N Engl J Med. 2023. PMID: 37272535 Clinical Trial.
Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on "Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891-9895".
Rayson D, Gandhi S, Joy AA, Brezden-Masley C, Gelmon KA, Sehdev S, Cescon D, Chia S. Rayson D, et al. Among authors: sehdev s. Curr Oncol. 2023 May 16;30(5):5050-5053. doi: 10.3390/curroncol30050381. Curr Oncol. 2023. PMID: 37232839 Free PMC article.
Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel.
Papp KA, Melosky B, Sehdev S, Hotte SJ, Beecker JR, Kirchhof MG, Turchin I, Dutz JP, Gooderham MJ, Gniadecki R, Hong CH, Lambert J, Lynde CW, Prajapati VH, Vender RB. Papp KA, et al. Among authors: sehdev s. Dermatol Ther (Heidelb). 2023 Apr;13(4):867-889. doi: 10.1007/s13555-023-00905-3. Epub 2023 Mar 16. Dermatol Ther (Heidelb). 2023. PMID: 36929121 Free PMC article.
24 results